Key releases

Key releases are ad hoc announcements pursuant to SIX Swiss Exchange Art. 53 LR

July 1, 2026
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States
April 23, 2026
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency
March 11, 2026
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering
March 5, 2026
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency¹, and Core EBITDA² of 1.211 billion USD, Growing 18.9% at Constant Currency
February 16, 2026
Galderma Announces Appointment of New Chief Financial Officer
December 8, 2025
Galderma Welcomes Increased Equity Investment From L’Oréal
October 23, 2025
Galderma Delivers Record Net Sales of 3.737 Billion USD in the First Nine Months of 2025 and 15.0% Year-on-Year Growth at Constant Currency, Raises Full-Year Guidance
July 24, 2025
Galderma Delivers Record First Half 2025 Net Sales of 2.448 Billion USD and 12.2% Year-on-Year Growth at Constant Currency, Raises Full-Year Top-Line Guidance
July 1, 2025
Galderma Announces Departure of Its Chief Financial Officer
May 28, 2025
Galderma Buys Back Shares Worth CHF 233 Million in the Context of Accelerated Bookbuild Offering
Displaying 1 - 10 of 23